NEW YORK (GenomeWeb News) – Singapore cancer diagnostics firm Clearbridge BioMedics announced on Wednesday the closing of a Series B financing round, bringing in S$9.0 million (US$7.2 million).

The financing will be used to further develop Clearbridge's ClearCell System, a non-biomarker-based platform for detecting, isolating, and retrieving circulating tumor cells from blood. The system consists of the ClearCell unit and single-use microfluidic biochips called CTChips.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: Leukemia-like disease in soft-shell clams, mNET-seq method for profiling growing transcripts, and more.

While James Watson and Francis Crick are credited for discovering the structure of DNA, Rich proved their theory of a double helix structure was correct when he produced a distinct image of the structure.

Nature News reports that early users of Oxford Nanopore's hand-held MinIon are giddy about the technology and its uses. 

According to MIT Technology Review, Apple is collaborating with researchers to develop apps for consumer DNA testing.